Oral Proteins & Peptides Market

The global Oral proteins and peptides market is projected to reach USD 7.38 billion in 2024 will increase to USD 20.36 billion by 2029, with a compound annual growth rate (CAGR) of 22.5% from 2024 to 2029. The growth of oral proteins and peptides market ascribed to major factors such as  increasing  prevalcne of chronic diseases like diabetes, CNS disroders and advancement in drug delivery technologies. On the other hand, high cost is associated with drug development and stringent regulatory approval process are projected to impede market growth.

Novo Nordisk A/S (Denmark), AbbVie Inc. (US), and Pfizer Inc. (US) holding the significant global market share and the global Oral proteins and peptides market is highly cosolidated.

To know about the assumptions considered for the study download the pdf brochure

Novo Nordisk A/S (Denmark)

Novo Nordisk A/S is headquartered in Denmark and currently operates as a leading pharmaceutical company around the world, especially in antidiabetic medications. Due to its wide portfolio of products, vast geographic presence, and well-known global brand, the company has been able to establish itself as a leader in the market. The focused research and manufacturing capabilities of the company with regard to insulins and GLP-1 products, of which RYBELSUS is one, have also significantly contributed toward the success of the company. The company increased its share in the global market for GLP-1 therapies to 55.3% over the period through the first quarter of 2024, significantly higher from 50.8% in 2021. The companies R&D expenditure at US$4.7 billion last year had given great strength to this position, mainly due to its movement into oral versions of the existing drugs like semaglutide that have huge scope and applications.

AbbVie Inc. (US)

AbbVie Inc stands at the number two spot for a US pharmaceutical company focused on oral proteins and peptides. The company oral peptides like linaclotide,  along with AbbVie has seen intense focus on  other oral peptide products atogepant and ubrogepant, where it stands ostensibly to take a chunk of the market. The companies strategic emphasis on gastrointestinal diseases, AbbVie has partly managed to stay ahead in the market through linaclotide. Furthermore, AbbVie has been proactive in forming strategic partnerships and collaborations to advance its product portfolio of oral proteins and peptides. These partnerships with biotech firms, academic institutions, and contract research organizations (CROs) help the company access cutting-edge technologies and novel delivery methods, expanding its footprint in the market.

Pfizer Inc. (US)

Pfizer Inc. is one of the US-based global health giants, entering the oral peptide market through NURTEC ODT - a CGRP receptor antagonist used for the treatment of episodic migraines. Pfizer's pipeline seems very strong; one of the drugs in its pipeline is Danuglipron, which is an oral GLP-1 receptor agonist in phase II clinical development. Pfizer has also focused on business acquisitions to focus on . For example, NURTEC ODT became part of Pfizer portfolio through the acquisition of Biohaven Pharmaceutical in October 2022.

Related Reports:

Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]